Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle.

Reliance on hepatitis C virus (HCV) replicon systems and protein-based screening assays has led to treatments that target HCV viral replication proteins. The model does not encompass other viral replication cycle steps such as entry, processing, assembly and secretion, or viral host factors. We previously applied a phenotypic high-throughput screening platform based on an infectious HCV system and discovered an aryloxazole-based anti-HCV hit. Structure-activity relationship studies revealed several compounds exhibiting EC50 values below 100 nM. Lead compounds showed inhibition of the HCV pseudoparticle entry, suggesting a different mode of action from existing HCV drugs. Hit 7a and lead 7ii both showed synergistic effects in combination with existing HCV drugs. In vivo pharmacokinetics studies of 7ii showed high liver distribution and long half-life without obvious hepatotoxicity. The lead compounds are promising as preclinical candidates for the treatment of HCV infection and as molecular probes to study HCV pathogenesis.

[1]  Shanshan He,et al.  Evaluation of Antiviral Drug Synergy in an Infectious HCV System , 2016, Antiviral therapy.

[2]  M. Ferrer,et al.  Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay. , 2015, Antiviral research.

[3]  Noel Southall,et al.  Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection , 2015, Journal of medicinal chemistry.

[4]  Ligong Chen,et al.  Discovery of Imidazo[1,2-α][1,8]naphthyridine Derivatives as Potential HCV Entry Inhibitor. , 2015, ACS medicinal chemistry letters.

[5]  Cameron J. Schweitzer,et al.  Border Control in Hepatitis C Virus Infection: Inhibiting Viral Entry. , 2015, ACS infectious diseases.

[6]  P. Ferenci,et al.  Treatment of hepatitis C in difficult-to-treat patients , 2015, Nature Reviews Gastroenterology &Hepatology.

[7]  E. Callaway.  Hepatitis C drugs not reaching poor , 2014, Nature.

[8]  Noel Southall,et al.  Novel Cell-Based Hepatitis C Virus Infection Assay for Quantitative High-Throughput Screening of Anti-Hepatitis C Virus Compounds , 2013, Antimicrobial Agents and Chemotherapy.

[9]  T. Liang,et al.  Current progress in development of hepatitis C virus vaccines , 2013, Nature Medicine.

[10]  T. Liang,et al.  Current and future therapies for hepatitis C virus infection. , 2013, The New England journal of medicine.

[11]  Maria F. Sassano,et al.  Automated design of ligands to polypharmacological profiles , 2012, Nature.

[12]  F. Wong-Staal,et al.  Discovery of highly potent small molecule Hepatitis C Virus entry inhibitors. , 2011, Bioorganic & medicinal chemistry letters.

[13]  M. Poss,et al.  A Novel Small Molecule Inhibitor of Hepatitis C Virus Entry , 2010, PLoS pathogens.

[14]  H. Te,et al.  Epidemiology of hepatitis B and C viruses: a global overview. , 2010, Clinics in liver disease.

[15]  R. Schinazi,et al.  Combinations of 2'-C-Methylcytidine Analogues with Interferon-α2b and Triple Combination with Ribavirin in the Hepatitis C Virus Replicon System , 2008, Antiviral chemistry & chemotherapy.

[16]  C. Cheng‐Mayer,et al.  Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  B. Roth,et al.  Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications , 2000, Circulation.

[18]  J. Hoofnagle,et al.  Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C , 2000, Annals of Internal Medicine.

[19]  R. Obach,et al.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[20]  D. Amacher.  Serum transaminase elevations as indicators of hepatic injury following the administration of drugs. , 1998, Regulatory toxicology and pharmacology : RTP.

[21]  M. Prichard,et al.  A three-dimensional model to analyze drug-drug interactions. , 1990, Antiviral research.

[22]  Y. Goto,et al.  Studies on Azole Compounds. III. Reactions of Oxazole N-Oxides with Phosphoryl Chloride and Acetic Anhydride , 1971 .

[23]  B. Largent,et al.  Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. , 2000, Molecular pharmacology.